ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

December 06, 2007 13:13 ET

ALDA's T36® Formulation Kills MRSA in 1 Minute

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 6, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) (the "Company") announces that new tests have shown the Company's T36® formulation to be completely effective against Methicillin-Resistant Staphylococcus aureus ("MRSA") within one minute. First discovered in 1961 in the UK, MRSA is now found worldwide and is able to survive treatment with a number of antibiotics, including penicillin, methicillin, and cephalosporins. Often referred to in the press as a "superbug", MRSA is especially troublesome in hospital-acquired infections but is increasingly found outside of medical facilities.

Dr. Terrance Owen, President & CEO, states, "We were confident that the T36® formulation would kill MRSA in our standard three-minute test because it has been successfully tested against normal Staphylococcus aureus a number of times. However, we were urged by our advisors to test the formulation against MRSA and decided to try a one-minute test. Given that the T36® formulation disrupts the physical structure of infectious organisms, rather than interfering with metabolic pathways, we were not expecting any microbial resistance, even from MRSA. Nevertheless, ALDA is especially pleased that T36® killed MRSA in one minute."

The tests against MRSA were conducted at an independent laboratory in the US to partially satisfy the registration requirements of Health Canada, the FDA and the European Medicines Agency.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patent-pending T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    (604) 521-8322 (FAX)
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521-8300 Ext. 3
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222